vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
APTARGROUP, INC. is the larger business by last-quarter revenue ($982.9M vs $708.5M, roughly 1.4× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 7.4%, a 11.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 10.8%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $53.3M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 3.9%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ATR vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $982.9M | $708.5M |
| Net Profit | $72.8M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 10.9% | 21.6% |
| Net Margin | 7.4% | 19.1% |
| Revenue YoY | 10.8% | 32.0% |
| Net Profit YoY | -7.5% | 15.5% |
| EPS (diluted) | $1.12 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $982.9M | — | ||
| Q4 25 | $962.7M | $708.5M | ||
| Q3 25 | $961.1M | $659.9M | ||
| Q2 25 | $966.0M | $603.3M | ||
| Q1 25 | $887.3M | $558.6M | ||
| Q4 24 | $848.1M | $536.6M | ||
| Q3 24 | $909.3M | $533.3M | ||
| Q2 24 | $910.1M | $528.1M |
| Q1 26 | $72.8M | — | ||
| Q4 25 | $74.3M | $135.1M | ||
| Q3 25 | $127.9M | $111.1M | ||
| Q2 25 | $111.7M | $90.3M | ||
| Q1 25 | $78.8M | $114.6M | ||
| Q4 24 | $100.9M | $117.0M | ||
| Q3 24 | $100.0M | $96.4M | ||
| Q2 24 | $90.5M | $88.4M |
| Q1 26 | 10.9% | — | ||
| Q4 25 | 11.0% | 21.6% | ||
| Q3 25 | 14.2% | 21.5% | ||
| Q2 25 | 14.9% | 20.9% | ||
| Q1 25 | 12.8% | 20.3% | ||
| Q4 24 | 14.2% | 23.4% | ||
| Q3 24 | 15.2% | 21.1% | ||
| Q2 24 | 13.8% | 19.9% |
| Q1 26 | 7.4% | — | ||
| Q4 25 | 7.7% | 19.1% | ||
| Q3 25 | 13.3% | 16.8% | ||
| Q2 25 | 11.6% | 15.0% | ||
| Q1 25 | 8.9% | 20.5% | ||
| Q4 24 | 11.9% | 21.8% | ||
| Q3 24 | 11.0% | 18.1% | ||
| Q2 24 | 9.9% | 16.7% |
| Q1 26 | $1.12 | — | ||
| Q4 25 | $1.13 | $4.65 | ||
| Q3 25 | $1.92 | $3.86 | ||
| Q2 25 | $1.67 | $3.10 | ||
| Q1 25 | $1.17 | $3.67 | ||
| Q4 24 | $1.48 | $3.67 | ||
| Q3 24 | $1.48 | $3.01 | ||
| Q2 24 | $1.34 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $229.5M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $459.1M |
| Total Assets | $5.1B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $229.5M | — | ||
| Q4 25 | $409.5M | $497.0M | ||
| Q3 25 | $264.8M | $285.4M | ||
| Q2 25 | $169.8M | $46.3M | ||
| Q1 25 | $136.8M | $441.4M | ||
| Q4 24 | $226.2M | $669.4M | ||
| Q3 24 | $327.9M | $656.9M | ||
| Q2 24 | $223.9M | $510.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.7B | $459.1M | ||
| Q3 25 | $2.8B | $293.6M | ||
| Q2 25 | $2.7B | $172.4M | ||
| Q1 25 | $2.5B | $593.6M | ||
| Q4 24 | $2.5B | $825.5M | ||
| Q3 24 | $2.5B | $881.4M | ||
| Q2 24 | $2.4B | $763.6M |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.3B | $2.0B | ||
| Q3 25 | $5.1B | $1.8B | ||
| Q2 25 | $4.9B | $1.6B | ||
| Q1 25 | $4.5B | $1.9B | ||
| Q4 24 | $4.4B | $2.1B | ||
| Q3 24 | $4.6B | $2.1B | ||
| Q2 24 | $4.5B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | $53.3M | $188.1M |
| FCF MarginFCF / Revenue | 5.4% | 26.6% |
| Capex IntensityCapex / Revenue | 6.7% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $327.0M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $183.7M | $192.7M | ||
| Q3 25 | $177.6M | $246.2M | ||
| Q2 25 | $126.0M | $148.5M | ||
| Q1 25 | $82.7M | $125.8M | ||
| Q4 24 | $178.2M | $190.7M | ||
| Q3 24 | $229.3M | $149.1M | ||
| Q2 24 | $143.6M | $116.4M |
| Q1 26 | $53.3M | — | ||
| Q4 25 | $96.9M | $188.1M | ||
| Q3 25 | $114.3M | $235.5M | ||
| Q2 25 | $62.5M | $142.4M | ||
| Q1 25 | $25.9M | $115.8M | ||
| Q4 24 | $112.2M | $183.0M | ||
| Q3 24 | $162.7M | $138.5M | ||
| Q2 24 | $75.4M | $103.5M |
| Q1 26 | 5.4% | — | ||
| Q4 25 | 10.1% | 26.6% | ||
| Q3 25 | 11.9% | 35.7% | ||
| Q2 25 | 6.5% | 23.6% | ||
| Q1 25 | 2.9% | 20.7% | ||
| Q4 24 | 13.2% | 34.1% | ||
| Q3 24 | 17.9% | 26.0% | ||
| Q2 24 | 8.3% | 19.6% |
| Q1 26 | 6.7% | — | ||
| Q4 25 | 9.0% | 0.6% | ||
| Q3 25 | 6.6% | 1.6% | ||
| Q2 25 | 6.6% | 1.0% | ||
| Q1 25 | 6.4% | 1.8% | ||
| Q4 24 | 7.8% | 1.4% | ||
| Q3 24 | 7.3% | 2.0% | ||
| Q2 24 | 7.5% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.47× | 1.43× | ||
| Q3 25 | 1.39× | 2.22× | ||
| Q2 25 | 1.13× | 1.65× | ||
| Q1 25 | 1.05× | 1.10× | ||
| Q4 24 | 1.77× | 1.63× | ||
| Q3 24 | 2.29× | 1.55× | ||
| Q2 24 | 1.59× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
